Companies › BlueSky Immunotherapies
1 active drug program in 2 registered trials: 2 Phase 1; Infectious disease, Oncology; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FluBHPVE6E7 Live attenuated influenza virus expressing HPV16 E6 and E7 therapeutic vaccine | – | Phase 1 | HPV Infection; Oropharyngeal Squamous Cell Carcinoma (SCC) | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05829629 | FluBHPVE6E7 | Phase 1 | HPV Infection | Infectious disease | Sep 2025 |
| NCT06589609 | FluBHPVE6E7 | Phase 1 | Oropharyngeal Squamous Cell Carcinoma (SCC) | Oncology | Nov 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.